The skin permeation mechanism of ketotifen: evaluation of permeation pathways and barrier components in the stratum corneum. 2000

K Inoue, and K Ogawa, and Y Suzuki, and J Okada, and A Kusai, and M Ikeda, and K Nishimura
Product Development Laboratories, Sankyo Company, Limited, Tokyo, Japan.

To evaluate the pathways and barrier components in the stratum corneum (SC) for the permeation of ketotifen, the effect of delipidization on the permeation and partition was examined under several donor pHs. Assuming that ionized ketotifen (KTH+) and un-ionized ketotifen (KT) contribute independently in both permeation and partition, the intrinsic permeability coefficients and SC/water partition coefficients of both species were estimated. Delipidization enlarged the permeability of KTH+ 100 times. This suggested that the lipid phase functions as the barrier against KTH+. KT has an intrinsic permeability 100 times larger than that of KTH+. Delipidization did not result in a significant change in permeability of KT. This suggested that the permeability of KT through the lipid phase is comparable to that through the aqueous phase in delipidized SC; that is, the lipid phase functions as a highly permeable pathway for KT. On the other hand, the permeability coefficient of KT through delipidized SC was 1/34 of that through the pure aqueous layer, which had a thickness equivalent to SC. Since this suggests that the permeability of KT through the proteinaceous phase is much lower than that through the aqueous phase, the proteinaceous phase can be assumed to function as a barrier against the permeation of KT. From these results, it is concluded that the predominant permeation pathway for KT is through the lipid phase. The SC/water partition coefficient of KT was cut in half by delipidization, but the value was still more than 100. These results show that the proteinaceous phase functions not only as the barrier, but also as the depot for KT. The knowledge obtained here will be useful for formulation design and for the selection of enhancers in a transdermal therapeutic system of ketotifen.

UI MeSH Term Description Entries
D007665 Ketotifen A cycloheptathiophene blocker of histamine H1 receptors and release of inflammatory mediators. It has been proposed for the treatment of asthma, rhinitis, skin allergies, and anaphylaxis. 4,9-Dihydro-4-(1-methyl-4-piperidylidene)-10H-benzo(4,5)-cyclohepta(1,2-b)thiophen-10-one,Ketotifen Fumarate,Ketotifene,Ketotiphen,Ketotiphene,Zaditen,Fumarate, Ketotifen
D008055 Lipids A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed) Lipid
D008297 Male Males
D008812 Mice, Hairless Mutant strains of mice that produce little or no hair. Hairless Mice,Mice, Inbred HRS,Mice, hr,Hairless Mouse,Mice, HRS,Mouse, HRS,Mouse, Inbred HRS,HRS Mice,HRS Mice, Inbred,HRS Mouse,HRS Mouse, Inbred,Inbred HRS Mice,Inbred HRS Mouse,Mouse, Hairless
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D005079 Excipients Usually inert substances added to a prescription in order to provide suitable consistency to the dosage form. These include binders, matrix, base or diluent in pills, tablets, creams, salves, etc. Excipient,Stabilizing Agent,Stabilizing Agents,Suspending Agent,Suspending Agents,Agent, Stabilizing,Agent, Suspending,Agents, Stabilizing,Agents, Suspending
D006863 Hydrogen-Ion Concentration The normality of a solution with respect to HYDROGEN ions; H+. It is related to acidity measurements in most cases by pH pH,Concentration, Hydrogen-Ion,Concentrations, Hydrogen-Ion,Hydrogen Ion Concentration,Hydrogen-Ion Concentrations
D000465 Algorithms A procedure consisting of a sequence of algebraic formulas and/or logical steps to calculate or determine a given task. Algorithm
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000982 Antipruritics Agents, usually topical, that relieve itching (pruritus). Antipruritic,Antipruritic Agent,Antipruritic Drug,Antipruritic Agents,Antipruritic Drugs,Agent, Antipruritic,Agents, Antipruritic,Drug, Antipruritic,Drugs, Antipruritic

Related Publications

K Inoue, and K Ogawa, and Y Suzuki, and J Okada, and A Kusai, and M Ikeda, and K Nishimura
April 1999, International journal of cosmetic science,
K Inoue, and K Ogawa, and Y Suzuki, and J Okada, and A Kusai, and M Ikeda, and K Nishimura
December 2009, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
K Inoue, and K Ogawa, and Y Suzuki, and J Okada, and A Kusai, and M Ikeda, and K Nishimura
August 2010, Molecular pharmaceutics,
K Inoue, and K Ogawa, and Y Suzuki, and J Okada, and A Kusai, and M Ikeda, and K Nishimura
October 2013, The Journal of clinical and aesthetic dermatology,
K Inoue, and K Ogawa, and Y Suzuki, and J Okada, and A Kusai, and M Ikeda, and K Nishimura
January 2016, Journal of cosmetic science,
K Inoue, and K Ogawa, and Y Suzuki, and J Okada, and A Kusai, and M Ikeda, and K Nishimura
October 1997, Journal of pharmaceutical sciences,
K Inoue, and K Ogawa, and Y Suzuki, and J Okada, and A Kusai, and M Ikeda, and K Nishimura
November 2013, The Journal of clinical and aesthetic dermatology,
K Inoue, and K Ogawa, and Y Suzuki, and J Okada, and A Kusai, and M Ikeda, and K Nishimura
October 2008, Journal of pharmaceutical sciences,
K Inoue, and K Ogawa, and Y Suzuki, and J Okada, and A Kusai, and M Ikeda, and K Nishimura
December 2011, AAPS PharmSciTech,
K Inoue, and K Ogawa, and Y Suzuki, and J Okada, and A Kusai, and M Ikeda, and K Nishimura
January 1992, Acta pharmaceutica Nordica,
Copied contents to your clipboard!